Sana Biotechnology (SANA) Research & Development (2020 - 2026)
Sana Biotechnology recorded quarterly Research & Development of $28.7 million in Q1 2026, down 17.77% quarter-over-quarter from $34.9 million in Q4 2025, and down 22.78% year-over-year from $37.2 million in Q1 2025.
Sana Biotechnology's Research & Development history runs 7 years deep, the most recent figure standing at $28.7 million for Q1 2026.
- In Q1 2026, Research & Development fell 22.78% year-over-year to $28.7 million; the TTM figure through Mar 2026 stood at $123.5 million (down 19.36% YoY), while the FY2025 annual figure was $132.0 million, down 38.81% from the prior year.
- Research & Development came in at $28.7 million for Q1 2026 at Sana Biotechnology, down from $34.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $76.7 million in Q3 2022 to a low of $1.9 million in Q4 2024.
- A 5-year average of $48.9 million and a median of $56.4 million in 2024 frame the typical range for Research & Development.
- Across the five-year window, Research & Development plunged 89.05% in 2023 and soared 1738.11% in 2025, its largest moves.
- Sana Biotechnology's Research & Development stood at $63.9 million in 2022, then slumped by 89.05% to $7.0 million in 2023, then tumbled by 72.86% to $1.9 million in 2024, then jumped by 1738.11% to $34.9 million in 2025, then retreated by 17.77% to $28.7 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $28.7 million, $34.9 million, and $30.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Sana Biotechnology | 890.09 Mn | 890.09 Mn | - | 28.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.72 Mn |
| Dec 31, 2025 | 34.92 Mn |
| Sep 30, 2025 | 30.11 Mn |
| Jun 30, 2025 | 29.76 Mn |
| Mar 31, 2025 | 37.19 Mn |
| Dec 31, 2024 | 1.90 Mn |
| Sep 30, 2024 | 53.21 Mn |
| Jun 30, 2024 | 60.87 Mn |
| Mar 31, 2024 | 56.45 Mn |
| Dec 31, 2023 | 7.00 Mn |
| Sep 30, 2023 | 65.61 Mn |
| Jun 30, 2023 | 73.04 Mn |
| Mar 31, 2023 | 67.17 Mn |
| Dec 31, 2022 | 63.92 Mn |
| Sep 30, 2022 | 76.74 Mn |
| Jun 30, 2022 | 72.54 Mn |
| Mar 31, 2022 | 72.69 Mn |
| Dec 31, 2021 | 108.51 Mn |
| Sep 30, 2021 | 53.25 Mn |
| Jun 30, 2021 | 45.00 Mn |
| Mar 31, 2021 | 41.88 Mn |
| Dec 31, 2020 | 36.49 Mn |
| Sep 30, 2020 | 40.06 Mn |
| Jun 30, 2020 | 29.99 Mn |
| Mar 31, 2020 | 27.32 Mn |